02/08/2019 | News release | Distributed by Public on 02/11/2019 13:10
Davis Polk advised the joint book-running managers in connection with a $60 million SEC-registered common stock and pre-funded warrants offering by Aeglea BioTherapeutics, Inc. The common stock is listed on the NASDAQ Global Market under the symbol 'AGLE.'
Based in Austin, Texas, Aeglea is a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer.
The Davis Polk corporate team included partner Bruce K. Dallas and associates Emily Roberts and Stephanie Y. Cheng. The tax team included partner Rachel D. Kleinberg and associate Rebecca A. Rosen. The intellectual property and technology team included partner David R. Bauer and associate Yifu Chen. Members of the Davis Polk team are based in the Northern California and New York offices.